Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma

BACKGROUND: Based on improved clinical outcomes in randomized controlled clinical trials (RCTs) the FDA and EMA have approved bevacizumab with interferon, sunitinib, and pazopanib in the first-line treatment of low to intermediate risk metastatic clear cell renal cell carcinoma (mRCC). However, ther...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Haaland, Benjamin, Chopra, Akhil, Acharyya, Sanchalika, Fay, André P, Lopes, Gilberto de Lima
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2014
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4148555/
https://ncbi.nlm.nih.gov/pubmed/25127891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-592
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia